May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Fluocinolone Acetonide-Mediated Neuroprotection in S334-ter-4 Rat Retinal Degeneration
Author Affiliations & Notes
  • R. Iezzi
    Ophthalmology, Wayne State Univ/Kresge Eye Institute, Detroit, Michigan
  • I. V. Glybina
    Ophthalmology, Wayne State Univ/Kresge Eye Institute, Detroit, Michigan
  • A. Kennedy
    Ophthalmology, Wayne State Univ/Kresge Eye Institute, Detroit, Michigan
  • P. Ashton
    pSivida Corporation, Watertown, Massachusetts
  • G. W. Abrams
    Ophthalmology, Wayne State Univ/Kresge Eye Institute, Detroit, Michigan
  • Footnotes
    Commercial Relationships  R. Iezzi, None; I.V. Glybina, None; A. Kennedy, None; P. Ashton, pSivida, E; pSivida, P; pSivida, I; G.W. Abrams, None.
  • Footnotes
    Support  Ligon Research Center Of Vision, Research To Prevent Blidness, Foundation For Fighting Blindness
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2036. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Iezzi, I. V. Glybina, A. Kennedy, P. Ashton, G. W. Abrams; Fluocinolone Acetonide-Mediated Neuroprotection in S334-ter-4 Rat Retinal Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2036.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study neuroprotective effects of intravitreal fluocinolone acetonide (FA) in albino S334-ter-4 rats.

Methods: : S334ter rats aged four-weeks were divided into four groups: 0.5µg/day FA-loaded intravitreal drug-delivery implant (IDDI); 0.2µg/day FA-loaded IDDI; inactive IDDI; and unoperated controls. Electroretinography (ERG) and intraocular pressure (IOP) measurements were performed pre-operatively and every two weeks post-operatively. At twelve weeks, animals were sacrificed. Outer nuclear layer (ONL) and inner nuclear layer (INL) thicknesses were measured. ED-1 antibody-labelled microglial cell processes were counted. Total microglial cell counts were made via IBA-1 immunohistochemical staining in retina wholemounts.

Results: : After an eight week study period, inactive IDDI and unoperated S334ter rats demonstrated 50-60% reduction in ERG a- and b-wave amplitudes (p<0.001 for both groups). FA 0.2µg/day animals demonstrated 15% amplitude attenuations and FA 0.5µg/day animals a 30% reduction in a- and b-wave amplitudes. IOP remained normal. ONL thickness in FA 0.2µg/day-treated eyes was 25.8%±2.3% higher than in control group eyes (p<0.001) and 30.0%±2.1% higher than in IDDI-implanted eyes (p<0.001). In FA 0.5µg/day-treated eyes, ONL cell counts were 22.4%±2.8% higher than in control group eyes (p<0.001) and 22.3%±3.7% higher than in IDDI-implanted eyes (p<0.01). There was no statistically significant difference between unoperated control and IDDI-implanted control groups. No statistically significant difference between the two treated groups was found. INL cell counts did not show statistically significant differences across experimental groups. FA-treated groups demonstrated significantly fewer activated microglial cells and overall number of microglia in the photoreceptors, compared to control groups.

Conclusions: : Chronic intravitreal infusion of FA is neuroprotective in S334ter rats, preserves ONL cell morphology and ERG a- and b-wave amplitudes and reduces retinal neuroinflammation. Based on these findings, chronic intravitreal delivery of FA may have a therapeutic role in patients with retinitis pigmentosa.

Keywords: retinal degenerations: cell biology • neuroprotection • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×